Another public company is on Austin's horizon, this time a drugmaker heading for NYSE

Savara Inc. — an Austin pharmaceutical company working on treatments for respiratory diseases — has found a path to Wall Street, and it doesn't involve an initial public offering. The 10-year-old business announced Jan. 7 that it intends to buy San Diego-based Mast Therapeutics Inc. (NYSE: MSTX) in an all- stock deal. The deal is expected to close in the second quarter, and Mast's ticker symbol will change when the deal is done. If stockholders approve the deal, the combined company — which…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news